Irina-Mihaela Matache

Dr. Irina-Mihaela Matache

Department of Neurological Surgery, University of Chicago, Chicago, Illinois, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2023 in World Neurosurgery
Verified
Journal Article
Closed access
SMSneha Sai Mannam
Sneha Sai Mannam
RSRobert Subtirelu
Robert Subtirelu
DCDaksh Chauhan
Daksh Chauhan
HAHasan S. Ahmad
Hasan S. Ahmad
Irina-Mihaela MatacheIrina-Mihaela Matache
Irina-Mihaela Matache
JYJang Won Yoon
Jang Won Yoon

15 June 2023 in Interventional Neuroradiology
Verified
Journal Article
Open access
GSGeorgios Sioutas
Georgios Sioutas
JVJuan Vivanco-Suarez
Juan Vivanco-Suarez
OSOleg Shekhtman
Oleg Shekhtman
Irina-Mihaela MatacheIrina-Mihaela Matache
Irina-Mihaela Matache
MSMohamed M Salem
Mohamed M Salem
BJbrian jankowitz
brian jankowitz
Introduction: Chronic subdural hematoma (CSDH) is associated with high recurrence rates. Middle meningeal artery embolization (MMAE) has emerged as a promising treatment option. In this systematic review and meta-analysis, we aimed to assess the safety and efficacy of MMAE for CSDH using liquid embolic agents and compare them with particles. Methods: We systematically reviewed all studies describing MMAE for CSDH with liquid embolic agents, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Additionally, we included a cohort of patients from our institution using liquid and particle embolic agents. Data were analyzed using random-effects proportions and comparisons meta-analysis, and statistical heterogeneity was assessed. Results: A total of 18 studies with 507 cases of MMAE with liquid embolic agents (including our institutional experience) were included in the analysis. The success rate was 99% (95% confidence interval [CI]: 98–⁠100%), all complications rate was 1% (95% CI: 0–⁠5%), major complications rate was 0% (95% CI: 0–⁠0%), and mortality rate was 1% (95% CI: 0–⁠6%). The rate of hematoma size reduction was 97% (95% CI: 73–⁠100%), complete resolution 64% (95% CI: 33–⁠87%), radiographic recurrence 3% (95% CI: 1–⁠7%), and reoperation 3% (95% CI: 1–⁠7%). No significant differences in outcomes were found between liquid and particle embolic agents. Sensitivity analyses revealed that liquid embolic agents were associated with lower reoperation rates in upfront MMAE (risk ratio 0.13, 95% CI: 0.02–⁠0.95). Conclusion: MMAE with liquid embolic agents is safe and effective for the treatment of CSDH. Outcomes are comparable to particles, but liquids were associated with a decreased risk of reoperation in upfront MMAE. However, further studies are needed to support our findings.

25 June 2025 in Gels
Verified
Journal Article
Open access
PDF file
DVDenisa-Madalina Viezuina
Denisa-Madalina Viezuina
IBIrina Burlacu
Irina Burlacu
MAMadalina Aldea
Madalina Aldea
Irina-Mihaela MatacheIrina-Mihaela Matache
Irina-Mihaela Matache
AZAlexandra Daniela Rotaru Zavaleanu
Alexandra Daniela Rotaru Zavaleanu
SMSmaranda Mitran
Smaranda Mitran
Peripheral nerve injuries (PNIs) present a significant clinical challenge due to the inherently limited regenerative capacity of the adult nervous system. Conventional therapeutic strategies, such as nerve autografting and systemic pharmacological interventions, are often limited by donor site morbidity, restricted graft availability, and suboptimal drug bioavailability. In this context, gelatin-based hydrogels have emerged as a promising class of biomaterials due to their excellent biocompatibility, biodegradability, and structural similarity to the native extracellular matrix. These hydrogels could offer a highly tunable platform capable of supporting cellular adhesion, promoting axonal elongation, and enabling localized and sustained release of therapeutic agents. This narrative review synthesizes recent advances in the application of gelatin-based hydrogels for peripheral nerve regeneration, with a particular focus on their use as delivery vehicles for neurotrophic factors, stem cells, and pharmacologically active compounds. Additionally, this review provides a foundation for extending our ongoing preclinical study, evaluating the neuroregenerative effects of alpha-lipoic acid, B-complex vitamins, and a deproteinized hemoderivative in a murine PNI model. Although systemic administration has demonstrated promising neuroprotective effects, limitations related to local drug availability and off-target exposure highlight the need for site-specific delivery strategies. In this regard, gelatin hydrogels might represent an excellent candidate for localized, controlled drug delivery. The review concludes by discussing formulation techniques, manufacturing considerations, biological performance, and key translational and regulatory aspects.

3 September 2022 in Medicina
Verified
Journal Article
Open access
PDF file
MCMihail Cotorogea
Mihail Cotorogea
BPBogdan Pavel
Bogdan Pavel
Isac SebastianIsac Sebastian
Isac Sebastian
TTTeodora Telecan
Teodora Telecan
Irina-Mihaela MatacheIrina-Mihaela Matache
Irina-Mihaela Matache
Droc GabrielaDroc Gabriela
Droc Gabriela
Background and Objectives: Acute hematologic malignancies are a group of heterogeneous blood diseases with a high mortality rate, mostly due to acute respiratory failure (ARF). Acute respiratory distress syndrome (ARDS) is one form of ARF which represents a challenging clinical condition. The paper aims to review current knowledge regarding the variable pathogenic mechanisms, as well as therapeutic options for ARDS in acute hematologic malignancy patients. Data collection: We provide an overview of ARDS in patients with acute hematologic malignancy, from an etiologic perspective. We searched databases such as PubMed or Google Scholar, including articles published until June 2022, using the following keywords: ARDS in hematologic malignancy, pneumonia in hematologic malignancy, drug-induced ARDS, leukostasis, pulmonary leukemic infiltration, pulmonary lysis syndrome, engraftment syndrome, diffuse alveolar hemorrhage, TRALI in hematologic malignancy, hematopoietic stem cell transplant ARDS, radiation pneumonitis. We included relevant research articles, case reports, and reviews published in the last 18 years. Results: The main causes of ARDS in acute hematologic malignancy are: pneumonia-associated ARDS, leukostasis, leukemic infiltration of the lung, pulmonary lysis syndrome, drug-induced ARDS, radiotherapy-induced ARDS, diffuse alveolar hemorrhage, peri-engraftment respiratory distress syndrome, hematopoietic stem cell transplantation-related ARDS, transfusion-related acute lung injury. Conclusions: The short-term prognosis of ARDS in acute hematologic malignancy relies on prompt diagnosis and treatment. Due to its etiological heterogeneity, precision-based strategies should be used to improve overall survival. Future studies should focus on identifying the relevance of such etiologic-based diagnostic strategies in ARDS secondary to acute hematologic malignancy.

Verified
Journal Article
Open access
PDF file
EPEma Andreea Palastea
Ema Andreea Palastea
Irina-Mihaela MatacheIrina-Mihaela Matache
Irina-Mihaela Matache
EREugen Radu
Eugen Radu
OHOctavian Henegariu
Octavian Henegariu
OBOctavian Bucur
Octavian Bucur
Omics research is changing the way medicine develops new strategies for diagnosis, prevention, and treatment. With the surge of advanced machine learning models tailored for omicss analysis, recent research has shown improved results and pushed the progress towards personalized medicine. The dissection of multiple layers of genetic information has provided new insights into precision medicine, at the same time raising issues related to data abundance. Studies focusing on single-cell scale have upgraded the knowledge about gene expression, revealing the heterogeneity that governs the functioning of multicellular organisms. The amount of information gathered through such sequencing techniques often exceeds the human capacity for analysis. Understanding the underlying network of gene expression regulation requires advanced computational tools that can deal with the complex analytical data provided. The recent emergence of artificial intelligence-based frameworks, together with advances in quantum algorithms, has the potential to enhance multiomicsc analyses, increasing the efficiency and reliability of the gene expression profile prediction. The development of more accurate computational models will significantly reduce the error rates in interpreting large datasets. By making analytical workflows faster and more precise, these innovations make it easier to integrate and interrogate multi-omics data at scale. Deep learning (DL) networks perform well in terms of recognizing complex patterns and modeling non-linear relationships that enable the inference of gene expression profiles. Applications range from direct prediction of DNA sequence-informed predictive modeling to transcriptomic and epigenetic analysis. Quantum computing, particularly through quantum machine learning methods, is being explored as a complementary approach for predictive modeling, with potential applications to complex gene interactions in increasingly large and high-dimensional biological datasets. Together, these tools are reshaping the study of complex biological data, while ongoing innovation in this field is driving progress towards personalized medicine. Overall, the combination of high-resolution omics and advanced computational tools marks an important shift toward more precise and data-driven clinical decision-making.

31 October 2023 in Frontiers in Neurology
Verified
Journal Article
Open access
RSRobert C. Subtirelu
Robert C. Subtirelu
ETEric M. Teichner
Eric M. Teichner
AAArjun Ashok
Arjun Ashok
CPChitra Parikh
Chitra Parikh
STSahithi Talasila
Sahithi Talasila
AAAbass Alavi
Abass Alavi
Glioblastomas (GBM) are highly invasive, malignant primary brain tumors. The overall prognosis is poor, and management of GBMs remains a formidable challenge, necessitating novel therapeutic strategies such as dendritic cell vaccinations (DCVs). While many early clinical trials demonstrate an induction of an antitumoral immune response, outcomes are mixed and dependent on numerous factors that vary between trials. Optimization of DCVs is essential; the selection of GBM-specific antigens and the utilization of 18F-fludeoxyglucose Positron Emission Tomography (FDG-PET) may add significant value and ultimately improve outcomes for patients undergoing treatment for glioblastoma. This review provides an overview of the mechanism of DCV, assesses previous clinical trials, and discusses future strategies for the integration of DCV into glioblastoma treatment protocols. To conclude, the review discusses challenges associated with the use of DCVs and highlights the potential of integrating DCV with standard therapies.